Navigation Links
Hypertension treatment effective in reversing vascular damage
Date:6/17/2008

WINSTON-SALEM, N.C. A hypertension medication called olmesartan medoxomil is effective in reversing the narrowing of the arteries that occurs in patients with high blood pressure, according to a new study.

Carlos M. Ferrario, M.D., one of the study's lead investigators and director of the Hypertension and Vascular Research Center at Wake Forest University Baptist Medical Center, said, "We believe the data add to the growing evidence for the role of angiotensin receptor blockers in preventing or reversing vascular damage at many stages during this disease process."

The one-year study, titled Vascular Improvement with Olmesartan medoxomil Study (VIOS), was published in the current Journal of the American Society of Hypertension. The study evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with stage 1 hypertension.

Olmesartan medoxomil is marketed in the United States as Benicar and in Europe as Olmetec by Daiichi Sankyo, Inc., which funded the study.

After one year of treatment, olmesartan medoxomil improved the artery abnormalities in high blood pressure patients and returned arterial architecture to normal levels. This was not seen with the atenolol.

Olmesartan medoxomil is a member of a class of antihypertensive medications that help lower blood pressure by blocking the angiotensin II receptor on the blood vessels that causes constriction and increase blood pressure. This medication also blocks the release of a hormone that causes salt retention and increased blood volume.

Hypertension affects one in three Americans and, if left uncontrolled for a long time, can cause organ damage, as well as heart disease, stroke and other problems.

Olmesartan is currently being reviewed in several trials, including the Randomized Olmesartan and Diabetes Microalbuminuria Prevention study (ROADMAP), which is investigating the drug's effectiveness in preventing early stage kidney disease in 4,400 patients with type 2 diabetes.

The VIOS results were presented at the Hypertension 2008 symposium, a scientific conference co-hosted by the European and International Societies of Hypertension. Dr. Ferrario was in Berlin, Germany, for the symposium, where he conducted interviews on Sunday and yesterday with international media about the significance of the VIOS data.


'/>"/>

Contact: Ann Hopkins
ahopkins@wfubmc.edu
336-716-1280
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related biology news :

1. Rare genetic mutations protect against hypertension
2. Researchers discovery may lead to hypertension treatment
3. Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension
4. Understanding hypertension in African Americans proves elusive
5. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
6. Source of drug-tolerant tuberculosis possibly behind TB relapses, intensity of treatment
7. Novel therapeutic strategy for colon cancer treatment
8. New ballast treatment could protect Great Lakes fish
9. Quest for better treatment for effects of menopause
10. Sugar linkage could lead to better treatment for autoimmune diseases
11. Glypican-3 gene function in regulating body size helps inform novel cancer treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... 2017 , ... Energetiq Technology , a world leader ... Executive Officer (CEO) Debbie Gustafson has been appointed to the SEMI North America ... the electronics manufacturing supply chain. The mission of the SEMI NAAB is to ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm ... stem cell technologies for neurodegenerative diseases, announced today that ... Alliance for Regenerative Medicine,s (ARM) 5 th Annual Cell ... at 09:40 EDT in Boston . ... Chief Medical Officer & Chief Operating Officer, will participate in ...
(Date:4/19/2017)... Indiana (PRWEB) , ... April 18, 2017 , ... Alisa ... 2017 Distinguished Alumni Awards from the Purdue College of Pharmacy in Lafayette, Indiana. ... Purdue Pharmacy Program for achievements in their careers and other scientific endeavors. , ...
(Date:4/19/2017)... ... 19, 2017 , ... WHO: Peggy Lillis Foundation, the preeminent ... advocacy. Founded in 2010 in memory of a single-parent mom and kindergarten teacher ... the most-consulted source for patient-focused information on C. diff infections in the nation. ...
Breaking Biology Technology: